Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats

Clinical Science

Volumn 118, Issue 10, 2010, Pages 617-632

  Čertíková Chábová, Věra ^a,b   Walkowska, Agnieszka ^c   Kompanowska Jezierska, Elzbieta ^c   Sadowski, Janusz ^c   Kujal, Petr ^a,b   Vernerová, Zdenka ^a,b   Vaňourková, Zdeňa ^b,d   Kopkan, Libor ^b,d   Kramer, Herbert J ^e   Falck, John R ^f   Imig, John D ^g   Hammock, Bruce D ^h   Vaněčková, Ivana ^b,d   Červenka, Luděk ^a,b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^c MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^d Center for Cardiovascular Research   (Czech Republic)

^e UNIVERSITY OF BONN   (Germany)

^f UNIVERSITY OF TEXAS AT DALLAS   (United States)

^g MEDICAL COLLEGE OF WISCONSIN   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cytochrome P450 (CYP450); End organ damage; Hypertension; Renin angiotensin system (RAS); Soluble epoxide hydrolase

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; ARACHIDONIC ACID; CYTOCHROME P450; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; N CYCLOHEXYL N DODECYL UREA; N METHYLSULFONYL 12,12 DIBROMODODEC 11 ENAMIDE; NORADRENALIN; UNCLASSIFIED DRUG; VASOCONSTRICTOR AGENT; 11,12 EPOXY 5,8,14 EICOSATRIENOIC ACID; 11,12-EPOXY-5,8,14-EICOSATRIENOIC ACID; 20 HYDROXY 5,8,11,14 EICOSATETRAENOIC ACID; 20-HYDROXY-5,8,11,14-EICOSATETRAENOIC ACID; AMIDE; DDMS; DIHOMO GAMMA LINOLENIC ACID; DRUG DERIVATIVE; HYDROXYICOSATETRAENOIC ACID; SULFONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DRUG EFFECT; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; KIDNEY BLOOD VESSEL; KIDNEY HYPERTROPHY; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEINURIA; RAT; SCLEROSIS; TARGET ORGAN; TRANSGENIC RAT; WISTAR HANNOVER RAT; ANIMAL; BIOSYNTHESIS; BLOOD PRESSURE; DRUG SCREENING; KIDNEY CIRCULATION; METABOLISM; METHODOLOGY; MULTIPLE ORGAN FAILURE; SPRAGUE DAWLEY RAT;

8,11,14-EICOSATRIENOIC ACID; AMIDES; ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG EVALUATION, PRECLINICAL; HYDROXYEICOSATETRAENOIC ACIDS; HYPERTENSION; MALE; MULTIPLE ORGAN FAILURE; NOREPINEPHRINE; RATS; RATS, SPRAGUE-DAWLEY; RATS, TRANSGENIC; RENAL CIRCULATION; SULFONES; VASOCONSTRICTOR AGENTS;

EID: 77954063347     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20090459     Document Type: Article

References (60)

1. US Renal Data System: USRDS 2007. (2008) Chronic kidney disease. Am. J. Kidney Dis. 51, S63-S80
2. Bakris, G. L. and Ritz E., G. L. (2009) The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. J. Clin. Hypertens. 11, 144-147
3. Kobori, H., Nangaku, M., Navar, L. G. and Nishiyama, A. (2007) The intrarenal renin - angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol. Rev. 59, 251-287
4. Roman, R. J. (2002) P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 82, 131-185
5. Campbell, W. B. and Falck, J. R. (2007) Arachidonic acid metabolites as endothelium-derived hyperpolarizing factors. Hypertension 49, 590-596
6. Capdevila, J. H, Falck, J. R. and Imig, J. D. (2007) Role of the cytochrome P450 arachidonic acid monooxygenases in the control of systemic blood pressure and experimental hypertension. Kidney. Int. 72, 683-689
7. Alonso-Galicia, M., Maier, K. G., Greene, A. S., Cowley, A.W. and Roman, R. J. (2002) Role of 20-hydroxyeicosatetraenoic acid in the renal and vasoconstrictor actions of angiotensin II. Am. J. Physiol. Integr. Comp. Physiol. Physiol. 283, R60-R68
8. Joly, E., Seqqat, R., Flamion, B., Caron, N., Michal, A., Imig, J. D. and Kramp, R. (2006) Increased renal vascular reactivity to angiotensin II after unilateral nephrectomy in the rat involves 20-HETE. Am. J. Physiol. Integr. Comp. Physiol. 291, R977-R986
9. Muthalif, M. M., Karzoun, N. A., Gaber, L., Khandekar, Z., Benter, I. F., Saeed, A. F., Parmentier, J. H., Estes, A. and Malik, K. U. (2000) Angiotensin II-induced hypertension: contribution of Ras GTPase/mitogen-activated protein kinase and cytochrome P-450 metabolites. Hypertension 36, 604-609
10. Kaergel, E., Muller, D. N., Honeck, H., Theuer, J., Shagdarsuren, E., Mullally, A., Luft, F. C. and Schunck, W. H. (2002) P450-dependent arachidonic acid metabolism and angiotensin II-induced renal damage. Hypertension 40, 273-279
11. Čertíková Chábová, V., Kramer, H. J., Vaněčková, I., Vernerovav, Z., Eis, V., Tesař, V., Škaroupková, P., Thumová, M., Schejbalová, S., Husková, Z., Vaňourková, Z., Kolský, A., Imig, J. D. and Červenka, L. (2007) Effects of chronic cytochrome P-450 inhibition on the course of hypertension and end-organ damage in Ren-2 transgenic rats. Vasc. Pharmacol. 47, 145-159
12. Mullins, J. J., Peters, J. and Ganten, D. (1990) Fulminant hypertension in transgenic rats harboring the mouse Ren-2 gene. Nature 344, 541-544
13. Čertíková Chábová, V., Kramer H.J., Vaněčková, I., Thumová, M., Škaroupkovav, P., Tesar, V., Falck, J.R., Imig, J.D., Červenka and L., Červenka (2007) The roles of intrarenal 20-hydroxyeicosatetraenoic and epoxyeicosatrienoic acids in the regulation of renal function in hypertensive Ren-2 transgenic rats. Kidney Blood Press. Res. 30, 335-346
14. Wang, M. H., Brand-Schieber, E., Zand, B. A., Nguyen, X., Falck, J. R., Balu, N. and Schwartzman, M. L. (1998) Cytochrome P-450-derived arachidonic acid metabolism in the rat kidney: characterization of selective inhibitors. J. Pharmacol. Exp. Ther. 284, 966-973
15. Morisseau, C., Goodrow, W. H., Dowdy, D., Zheng, J., Greene, J. F., Sanborn, J. R. and Hammock, B. D. (1999) Potent urea and carbamate inhibitors of soluble epoxide hydrolase. Proc. Nat. Acad. Sci. U.S.A. 96, 8849-8854
16. Imig, J. D., Zhao, X., Capdevila, J. H., Morisseau, C. and Hammock, B. D. (2002) Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39, 690-694 (Pubitemid 34165207)
17. Vaněčková, I., Kramer, H. J., Bäcker, A., Schejbalová, S., Vernerová, Z., Eis, V., Opočenský, M., Dvořák, P. and Červenka, L. (2006) Early-onset endothelin receptor blockade in hypertensive heterozygous Ren-2 rats. Vasc. Pharmacol. 45, 163-170
18. Opočenský, M., Kramer, H. J., Bäcker, A., Vernerová, Z., Eis, V., Červenka, L. and Vaněč ková, I., (2006) Late-onset endothelin-A receptor blockade substantially improves survival rate in homozygous hypertensive Ren-2 rats. Hypertension 48, 965-971
19. Husková, Z., Kramer, H. J., Vaňourková, Z. and Červenka, L. (2006) Effects of changes in sodium balance on plasma and kidney angiotensin II levels in anesthetized and conscious Ren-2 transgenic rats. J. Hypertens. 24, 517-527
20. Husková, Z., Kramer, H. J., Thumová, M., Vaňourková, Z., Bürgelová, M., Teplan, V., Malý, J. and Červenka, L. (2006) Effects of anesthesia on plasma and kidney ANG II levels in normotensive and ANG II-dependent hypertensive rats. Kidney Blood Press. Res. 29, 74-83
21. Vaňourková, Z., Kramer, H. J., Husková, Z., Vaněčková, I., Opočenský, M., Čertíkovav Chábová, V., Tesař, V., Škaroupková, P., Thumová, M., Dohnalová, M., Mullins, J. J. and Červenka, L. (2006) AT1 receptor blockade is superior to conventional triple therapy in protecting against end-organ damage in Cyp1a1-Ren-2 transgenic rats with inducible hypertension. J. Hypertens. 24, 2465-2472
22. Sandberg, M. C. and Laborde, C. (2004) Glomerulosclerosis and tubulointerstitial fibrosis are attenuated with 17-β-estradiol in the aging Dahl salt sensitive rat. J. Am. Soc. Nephrol. 15, 1546-1556
23. Nakano, Y., Hirano, T., Uehara, K., Nishibayashi, S., Hattori, K., Aihara, M. and Yamada, Y. (2008) New rat model induced by anti-glomerular basement membrane antibody shows severe glomerular adhesion in early stage and quickly progresses to end-stage renal failure. Pathol. Int. 58, 361-370
24. Weibel, E. R. (1979) Stereological Methods, Practical Methods for Biological Morphometry, pp. 44-46, Academic Press, London
25. Lane, P. H., Steffes, M. W. and Mauer, M. S. (1992) Estimation of glomerular volume: a comparison of four methods. Kidney Int. 41, 1085-1089
26. Jacinto, S. M., Mullins, J. J. and Mitchell, K. D. (1999) Enhanced renal vascular responsiveness to angiotensin II in hypertensive ren-2 transgenic rats. Am. J. Physiol. 276, F315-F322
27. Kopkan, L., Kramer, H. J., Husková, Z., Vaňourková, Z,, Škaroupková, P., Thumová, M. and Červenka, L. (2005) The role of intrarenal angiotensin II in the development of hypertension in Ren-2 transgenic rats. J. Hypertens. 23, 1531-1539
28. Lee, M. A., Böhm, M., Paul, M., Bader, M., Ganten, U. and Ganten, D. (1996) Physiological characterization of the hypertensive transgenic rat TGR(mRen2)27. Am. J. Physiol. 270, E919-E929
29. Mitchell, K. D., Jacinto, S. M. and Mullins, J. J. (1997) Proximal tubular fluid, kidney, and plasma levels of angiotensin II in hypertensive Ren-2 transgenic rats. Am. J. Physiol. 273, F246-F253
30. Sarkis, A., Lopez, B. and Roman, R. J. (2004) Role of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids in hypertension. Curr. Opin. Nephrol. Hypertens. 13, 205-214
31. Zhao, X., Pollock, D. M., Zeldin, D. C. and Imig, J. D. (2003) Salt-sensitive hypertension after exposure to angiotensin is associated with inability to upregulate renal epoxygenases. Hypertension 42, 775-780 (Pubitemid 37237324)
32. Jung, O., Brandes, R. P., Kim, I-H., Schweda, F., Schmidt, R., Hammock, B. D., Busse, R. and Fleming, I. (2005) Soluble epoxide hypdrolase is a main effector of angiotensin II-induced hypertension. Hypertension 45, 759-765 (Pubitemid 40418378)
33. + channel in renal arterioles. Am. J. Physiol. 270, R228-R237
34. 2+ current. J. Physiol. 507, 771-781
35. Randriamboavonjy, V., Busse, R. and Fleming, I. (2003) 20-HETE-induced contraction of small coronary arteries depends on the activation of Rho-Kinase. Hypertension 41, 801-806 (Pubitemid 36314594)
36. Imig, J. D., Pham, B. T., LeBlanc, E. A., Reddy, K. M., Falck, J. R. and Inscho, E.W. (2000) Cytochrome P450 and cyclooxygenase metabolites contribute to the endothelin-1 afferent arteriolar vasoconstrictor and calcium responses. Hypertension 35, 307-312
37. Oyekan, A. O. and McGiff, J. C. (1998) Cytochrome P-450-derived eicosanoids participates in the renal functional effects of ET-1 in the anaesthetized rat. Am. J. Physiol. 274, R52-R61
38. Singh, H. and Schwartzman, M. L. (2008) Renal vascular cytochrome P450-derived eicosanoids in androgen-induced hypertension. Pharmacol. Rep. 60, 29-37
39. Quigley, R., Baum, M., Reddy, K. M., Griener, J. C. and Falck, J. R. (2000) Effects of 20-HETE and 19(S)-HETE on rabbit proximal straight tubule volume transport. Am. J. Physiol. Renal Physiol. 278, F949-F953
40. +-ATPase activity in the thick ascending loop of Henle. Am. J. Physiol. Integr. Comp. Physiol. 292, R2400-R2405
41. Hoagland, K. M., Flasch, A. K. and Roman, R. J. (2003) Inhibitors of 20-HETE formation promote salt-sensitive hypertension in rats. Hypertension 42, 669-673
42. Imig, J. D., Zhao, X., Falck, J. R., Wei, S. and Capdevila, J. H. (2001) Enhanced renal mircovascular reactivity to angiotensin II in hypertension is ameliorated by the sulfonimide analog of 11,12-epoxyeicosatrienoic acid. J. Hypertens. 19, 983-992 (Pubitemid 32436964)
43. Imig, J. D., Falck, J. R., Wei, S. and Capdevila, J. H. (2001) Epoxygenase metabolites contribute to nitric oxide-independent afferent arteriolar vasodilatation in response to bradykinin. J. Vasc. Res. 38, 247-255
44. Wang, D., Borrego-Conde, L. J., Falck, J. R., Sharma, K. K., Wilcox, C. S. and Umans, J. G. (2003) Contribution of nitric oxide, EDHF, and EETs to endothelium-dependent relaxation in renal afferent arterioles. Kidney Int. 63, 2187-2193
45. Kohagure, K., Endo, Y., Ito, O., Arima, S., Omata, K. and Ito, S. (2000) Endogenous nitric oxide and epoxyeicosatrienoic acids modulate angiotensin II-induced constriction in the rabbit afferent arteriole. Acta Physiol. Scand. 168, 107-112
46. Madhun, Z. T., Goldthwait, D. A., McKay, D., Hopfer, U. and Douglas, J. G. (1991) An epoxygenase metabolite of arachidonic acid mediates angiotensin II-induced rises in cytosolic calcium in rabbit proximal tubule epithelial cells. J. Clin. Invest. 88, 456-461
47. Sakairi, Y., Jacobson, H. R., Noland, D. T., Capdevila, J. H., Falck, J. R. and Breyer, M. D. (1995) 5,6-EET inhibits ion transport in collecting duct by stimulating endogenous prostaglandin synthesis. Am. J. Physiol. 268, F931-F939
48. Imig, J. D. (2005) Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am. J. Physiol. Renal Physiol. 289, F496-F503
49. Yoshida, Y., Kawamura, T., Ikoma, M., Fogo, A. and Ichikawa, I. (1989) Effects of antihypertensive drugs on glomerular morphology. Kidney Int. 36, 626-635 (Pubitemid 19239554)
50. Dworkin, L. D., Feiner, H. D., Parker, M. and Tolbert, E. (1991) Effects of nifedipine and enalapril on glomerular structure and function in uninephrectomized SHR. Kidney Int. 39, 1112-1117
51. Imig, J. D. and Hammock, B. D., (2009) Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat. Rev. Drug Discov. 8, 794-805
52. McGiff, J. C. (1991) Cytochrome P-450 metabolism of arachidonic acid. Ann. Rev. Pharmacol. Toxicol. 31, 339-169
53. Makita, K., Falck, J. R. and Capdevila, J. H. (1996) Cytochrome P450, the arachidonic acid cascade, and hypertension: new vistas for old enzyme system. FASEB J. 10, 1456-1463
54. Sakuma, S., Usa, K. and Fujimoto, Y. (2006) 15- hydroperoxyeicosapentaenoic acid, but not eicosapentaenoic acid, shifts arachidonic acid away from cyclooxygenase pathway into acyl-CoA synthetase pathway in rabbit kidney medulla microsomes. Prostaglandins Leukotriene Essent. Fatty Acids 75, 69-74
55. Spector, A. A. (2009) Arachidonic acid cytochrome P450 epoxygenase pathway. J. Lipid. Res. 50, S52-S60
56. Zicha, J. and Kuneš, J., (1999) Ontogenetic aspects of hypertension development: analysis in the rat. Physiol. Rev. 79, 1227-1282
57. Muthalif, M. M., Benter, L. F., Karzoun, N., Fatima, S., Harper, J., Uddin, M. R. and Malik, K. U. (1998) 20-Hydroxyeicosatetraenoic acid mediates calcium/calmodulin dependent protein kinase II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. Proc. Natl. Acad. Sci. U.S.A. 95, 12701-12706
58. Parmentier, J-H., Muthalif, M. M., Nishimoto, A. T. and Malik, K. U. (2001) 20-Hydroxyeicosatetraenoic acid mediates angiotensin II-induced phospholipase D activation in vascular smooth muscle cells. Hypertension 37, 623-629 (Pubitemid 32199039)
59. Yaghini, F. A., Zhang, C., Parmentier, J. H., Estes, A. M., Jafari, N., Schaefer, S. A. and Malik, K. U. (2005) Contribution of arachidonic acid metabolites derived via cytochrome P4504A to angiotensin II-induced neointimal growth. Hypertension 45, 1182-1187
60. Camara, N. O., Martins, J. O., Landgraf, R. G. and Jancar, S. (2009) Emerging roles for eicosanoids in renal diseases. Curr. Opin. Nephrol. Hypertens. 18, 21-27